Glucokinase activation is beneficial or toxic to cultured rat pancreatic islets depending on the prevailing glucose concentration

American Journal of Physiology - Endocrinology and Metabolism

Volumn 309, Issue 7, 2015, Pages E632-E639

  Roma, Leticia P ^a   Duprez, Jessica ^a   Jonas, Jean Christophe ^a,b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b FNRS   (Belgium)

Author keywords

Glucotoxicity; Insulin secretion; Pancreatic cell; Poptosis

Indexed keywords

CALCIUM; GLUCOKINASE; GLUCOSE; INSULIN; METALLOTHIONEIN 1A; METALLOTHIONEIN I; PREPROINSULIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THIOREDOXIN INTERACTING PROTEIN; UNCLASSIFIED DRUG; 3-CYCLOPENTYL-2-(4-METHANESULFONYLPHENYL)-N-THIAZOL-2-YL-PROPIONAMIDE; RO-28-0450; SULFONE; THIAZOLE DERIVATIVE;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOFLUORESCENCE; CALCIUM CELL LEVEL; CELL CULTURE; CELL FUNCTION; CELL SURVIVAL; DNA FRAGMENTATION; ENDOCRINE SYSTEM; ENZYME ACTIVATION; GENE CONTROL; GENE EXPRESSION; GLUCOSE METABOLISM; GLUCOTOXICITY; INSULIN RELEASE; MALE; NONHUMAN; PANCREAS ISLET BETA CELL; PHENOTYPE; PRIORITY JOURNAL; RAT; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PANCREAS ISLET; PHYSIOLOGY; WISTAR RAT;

ANIMALS; APOPTOSIS; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; GLUCOKINASE; GLUCOSE; ISLETS OF LANGERHANS; MALE; RATS; RATS, WISTAR; SULFONES; THIAZOLES;

EID: 84943328579     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00154.2015     Document Type: Article

References (48)

1. Bensellam M, Laybutt DR, Jonas JC. The molecular mechanisms of pancreatic β-cell glucotoxicity: Recent findings and future research directions. Mol Cell Endocrinol 364: 1-27, 2012.
2. Bensellam M, Van Lommel L, Overbergh L, Schuit FC, Jonas JC. Cluster analysis of rat pancreatic islet gene mRNA levels after culture in low-, intermediate-and high-glucose concentrations. Diabetologia 52: 463-476, 2009.
3. Bonadonna RC, Heise T, Arbet-Engels C, Kapitza C, Avogaro A, Grimsby J, Zhi J, Grippo JF, Balena R. Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab 95: 5028-5036, 2010.
4. Challis BG, Harris J, Sleigh A, Isaac I, Orme SM, Seevaratnam N, Dhatariya K, Simpson HL, Semple RK. Familial adult onset hyperinsulinism due to an activating glucokinase mutation: implications for pharmacological glucokinase activation. Clin Endocrinol (Oxf) 81: 855-861, 2014.
5. Chen J, Saxena G, Mungrue IN, Lusis AJ, Shalev A. Thioredoxininteracting protein: a critical link between glucose toxicity and β-cell apoptosis. Diabetes 57: 938-944, 2008.
6. De Ceuninck F, Kargar C, Ilic C, Caliez A, Rolin JO, Umbdenstock T, Vinson C, Combettes M, de FB, Harley E, Sadlo M, Lefevre AL, Broux O, Wierzbicki M, Fourquez JM, Perron-Sierra F, Kotschy A, Ktorza A. Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans. Br J Pharmacol 168: 339-353, 2013.
7. Dhanesha N, Joharapurkar A, Shah G, Kshirsagar S, Patel V, Patel K, Bahekar R, Jain M. Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice. Eur J Pharmacol 714: 188-192, 2013.
8. Doliba NM, Qin W, Najafi H, Liu C, Buettger CW, Sotiris J, Collins HW, Li C, Stanley CA, Wilson DF, Grimsby J, Sarabu R, Naji A, Matschinsky FM. Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics. Am J Physiol Endocrinol Metab 302: E87-E102, 2012.
9. Duprez J, Roma LP, Close AF, Jonas JC. Protective antioxidant and antiapoptotic effects of ZnCl2 in rat pancreatic islets cultured in low and high glucose concentrations. PLoS One 7: e46831, 2012.
10. Elouil H, Bensellam M, Guiot Y, Vander Mierde D, Pascal SM, Schuit FC, Jonas JC. Acute nutrient regulation of the unfolded protein response and integrated stress response in cultured rat pancreatic islets. Diabetologia 50: 1442-1452, 2007.
11. Futamura M, Yao J, Li X, Bergeron R, Tran JL, Zycband E, Woods J, Zhu Y, Shao Q, Maruki-Uchida H, Goto-Shimazaki H, Langdon RB, Erion MD, Eiki J, Zhou YP. Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves β-cell mass in the Zucker diabetic fatty rat. Diabetologia 55: 1071-1080, 2012.
12. Gill D, Brocklehurst KJ, Brown HW, Smith DM. Upregulation of β-cell genes and improved function in rodent islets following chronic glucokinase activation. J Mol Endocrinol 47: 59-67, 2011.
13. Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW, Guertin KR, Hilliard DW, Kester RF, Mahaney PE, Marcus L, Qi L, Spence CL, Tengi J, Magnuson MA, Chu CA, Dvorozniak MT, Matschinsky FM, Grippo JF. Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301: 370-373, 2003.
14. Hanson GT, Aggeler R, Oglesbee D, Cannon M, Capaldi RA, Tsien RY, Remington SJ. Investigating mitochondrial redox potential with redox-sensitive green fluorescent protein indicators. J Biol Chem 279: 13044-13053, 2004.
15. Heredia VV, Thomson J, Nettleton D, Sun S. Glucose-induced conformational changes in glucokinase mediate allosteric regulation: transient kinetic analysis. Biochemistry 45: 7553-7562, 2006.
16. Hinke SA, Hellemans K, Schuit FC. Plasticity of the β cell insulin secretory competence: preparing the pancreatic β cell for the next meal. J Physiol 558: 369-380, 2004.
17. Jauslin PM, Karlsson MO, Frey N. Identification of the mechanism of action of a glucokinase activator from oral glucose tolerance test data in type 2 diabetic patients based on an integrated glucose-insulin model. J Clin Pharmacol 52: 1861-1871, 2012.
18. Jonas JC, Bensellam M, Duprez J, Elouil H, Guiot Y, Pascal SM. Glucose regulation of islet stress responses and β-cell failure in type 2 diabetes. Diabetes Obes Metab 11, Suppl 4: 65-81, 2009.
19. Jonas JC, Sharma A, Hasenkamp W, Ilkova H, Patane G, Laybutt R, Bonner-Weir S, Weir GC. Chronic hyperglycemia triggers loss of pancreatic β cell differentiation in an animal model of diabetes. J Biol Chem 274: 14112-14121, 1999.
20. Kamata K, Mitsuya M, Nishimura T, Eiki J, Nagata Y. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure 12: 429-438, 2004.
21. Khaldi MZ, Guiot Y, Gilon P, Henquin JC, Jonas JC. Increased glucose sensitivity of both triggering and amplifying pathways of insulin secretion in rat islets cultured for one week in high glucose. Am J Physiol Endocrinol Metab 287: E207-E217, 2004.
22. Kiyosue A, Hayashi N, Komori H, Leonsson-Zachrisson M, Johnsson E. Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab 15: 923-930, 2013.
23. Leggate J, Allain R, Isaac L, Blais BW. Microplate fluorescence assay for the quantification of double stranded DNA using SYBR Green I dye. Biotechnol Lett 28: 1587-1594, 2006.
24. Liang Y, Najafi H, Smith RM, Zimmerman EC, Magnuson MA, Tal M, Matschinsky FM. Concordant glucose induction of glucokinase, glucose usage, and glucose-stimulated insulin release in pancreatic islets maintained in organ culture. Diabetes 41: 792-806, 1992.
25. Maechler P. Mitochondrial function and insulin secretion. Mol Cell Endocrinol 379: 12-18, 2013.
26. Martens GA, Cai Y, Hinke S, Stange G, Van de Casteele M, Pipeleers D. Glucose suppresses superoxide generation in metabolically responsive pancreatic β cells. J Biol Chem 280: 20389-20396, 2005.
27. Martens GA, Van de Casteele M. Glycemic control of apoptosis in the pancreatic β-cell: danger of extremes? Antioxid Redox Signal 9: 309-317, 2007.
28. Matschinsky FM. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 45: 223-241, 1996.
29. Matschinsky FM. GKAs for diabetes therapy: why no clinically useful drug after two decades of trying? Trends Pharmacol Sci 34: 90-99, 2013.
30. Matschinsky FM, Magnuson MA, Zelent D, Jetton TL, Doliba N, Han Y, Taub R, Grimsby J. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 55: 1-12, 2006.
31. Meininger GE, Scott R, Alba M, Shentu Y, Luo E, Amin H, Davies MJ, Kaufman KD, Goldstein BJ. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 34: 2560-2566, 2011.
32. Meyer AJ, Dick TP. Fluorescent protein-based redox probes. Antioxid Redox Signal 13: 621-650, 2010.
33. Nakamura A, Terauchi Y, Ohyama S, Kubota J, Shimazaki H, Nambu T, Takamoto I, Kubota N, Eiki J, Yoshioka N, Kadowaki T, Koike T. Impact of small-molecule glucokinase activator on glucose metabolism and β-cell mass. Endocrinology 150: 1147-1154, 2009.
34. Nissim I, Horyn O, Nissim I, Daikhin Y, Wehrli SL, Yudkoff M, Matschinsky FM. Effects of a glucokinase activator on hepatic intermediary metabolism: study with 13C-isotopomer-based metabolomics. Biochem J 444: 537-551, 2012.
35. Oh YS, Lee YJ, Park K, Choi HH, Yoo S, Jun HS. Treatment with glucokinase activator, YH-GKA, increases cell proliferation and decreases glucotoxic apoptosis in INS-1 cells. Eur J Pharm Sci 51: 137-145, 2014.
36. Pascal SM, Veiga-da-Cunha M, Gilon P, Van Schaftingen E, Jonas JC. Effects of fructosamine-3-kinase deficiency on function and survival of mouse pancreatic islets after prolonged culture in high glucose or ribose concentrations. Am J Physiol Endocrinol Metab 298: E586-E596, 2010.
37. Pipeleers D, Kiekens R, Ling Z, Wilikens A, Schuit F. Physiologic relevance of heterogeneity in the pancreatic β-cell population. Diabetologia 37, Suppl 2: S57-S64, 1994.
38. Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, Shelton KD, Lindner J, Cherrington AD, Magnuson MA. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic β-cell-specific gene knock-outs using Cre recombinase. J Biol Chem 274: 305-315, 1999.
39. Prentki M, Matschinsky FM, Madiraju SR. Metabolic signaling in fuel-induced insulin secretion. Cell Metab 18: 162-185, 2013.
40. Roma LP, Pascal SM, Duprez J, Jonas JC. Mitochondrial oxidative stress contributes differently to rat pancreatic islet cell apoptosis and insulin secretory defects after prolonged culture in a low non-stimulating glucose concentration. Diabetologia 55: 2226-2237, 2012.
41. Rutter GA, Pullen TJ, Hodson DJ, Martinez-Sanchez A. Pancreatic β-cell identity, glucose sensing and the control of insulin secretion. Biochem J 466: 203-218, 2015.
42. Sarre A, Gabrielli J, Vial G, Leverve XM, Assimacopoulos-Jeannet F. Reactive oxygen species are produced at low glucose and contribute to the activation of AMPK in insulin-secreting cells. Free Radic Biol Med 52: 142-150, 2012.
43. Terauchi Y, Sakura H, Yasuda K, Iwamoto K, Takahashi N, Ito K, Kasai H, Suzuki H, Ueda O, Kamada N. Pancreatic β-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose. J Biol Chem 270: 30253-30256, 1995.
44. Tornovsky-Babeay S, Dadon D, Ziv O, Tzipilevich E, Kadosh T, Schyr-Ben HR, Hija A, Stolovich-Rain M, Furth-Lavi J, Granot Z, Porat S, Philipson LH, Herold KC, Bhatti TR, Stanley C, Ashcroft FM, In't VP, Saada A, Magnuson MA, Glaser B, Dor Y. Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in β-cells. Cell Metab 19: 109-121, 2013.
45. Van de Casteele M, Kefas BA, Cai Y, Heimberg H, Scott DK, Henquin JC, Pipeleers D, Jonas JC. Prolonged culture in low glucose induces apoptosis of rat pancreatic β-cells through induction of c-myc. Biochem Biophys Res Commun 312: 937-944, 2003.
46. Wei P, Shi M, Barnum S, Cho H, Carlson T, Fraser JD. Effects of glucokinase activators GKA50 and LY2121260 on proliferation and apoptosis in pancreatic INS-1 β-cells. Diabetologia 52: 2142-2150, 2009.
47. Wilding JP, Leonsson-Zachrisson M, Wessman C, Johnsson E. Doseranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin. Diabetes Obes Metab 15: 750-759, 2013.
48. Winzell MS, Coghlan M, Leighton B, Frangioudakis G, Smith DM, Storlien LH, Ahren B. Chronic glucokinase activation reduces glycaemia and improves glucose tolerance in high-fat diet fed mice. Eur J Pharmacol 663: 80-86, 2011.